Clinical context map
Chronic kidney disease
End-stage renal disease
Hemodialysis
Renal anemia
{"id":"e0dbc0ad-92ce-4a1e-9cb1-be5eacf56ed2","slug":"top-eu-ckd-kidney-failure-trial-sites","status":"published","title":"Which EU Sites Anchor Phase II–III CKD and Kidney Failure Trials?","html":"\u003c!-- SEO VARIABLES\nslug: top-eu-ckd-kidney-failure-trial-sites\nmeta_description: CKD Phase II–III trials included 54 CTIS records; dialysis networks led site density, Germany and Spain drove 2026 capacity.\nkeywords: nephrology, chronic kidney disease, CKD, kidney failure, end-stage renal disease, end-stage kidney disease, hemodialysis, dialysis, renal anemia, kidney transplantation, Phase II, Phase III, small molecule, peptide, protein, enzyme, cell therapy, Europe, EU clinical trial sites, CTIS\n-->\n\n\u003c!-- META DESCRIPTION:\nAcross 54 CTIS Phase II–III CKD/kidney failure trial records, site activity clustered around dialysis/nephrology networks, with repeated appearances from TritonLife, First Dialysis Services Bulgaria, Nuvisan, Amsterdam UMC, Steno Diabetes Center Copenhagen, Vall d’Hebron, and Hospital Fundacion Jimenez Diaz.\n-->\n\n\u003cdiv style=\"background:#111315; color:#F2F2F2; font-family:Inter, ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif; padding:48px 24px 72px 24px;\">\n\u003cdiv style=\"max-width:768px; margin:0 auto;\">\n\n\u003csection style=\"background:linear-gradient(180deg,#122319 0%,#111315 100%); border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:32px; margin-bottom:64px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:16px;\">Clinical Trial Intelligence\u003c/div>\n\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Which EU Sites Anchor Phase II–III CKD and Kidney Failure Trials?\">\n\u003ch1 style=\"font-size:48px; line-height:56px; font-weight:650; letter-spacing:-0.035em; margin:0 0 12px 0; color:#F2F2F2;\">Which EU Sites Anchor Phase II–III CKD and Kidney Failure Trials?\u003c/h1>\n\u003cdiv style=\"font-size:13px; line-height:1.5; font-weight:600; color:#3FAE6F; margin:0 0 22px 0;\">Report date: 7 June 2026\u003c/div>\n\u003cp style=\"font-size:17px; line-height:1.65; font-weight:400; color:rgba(255,255,255,0.70); margin:0 0 28px 0;\">Across \u003cstrong style=\"color:#F2F2F2;\">54 CTIS Phase II–III records\u003c/strong>, CKD and kidney failure trials show two different operational patterns: broad dialysis-network deployment in Phase III and smaller nephrology specialist clusters in Phase II. The most repeated site/legal-site names were dialysis platforms and high-volume academic nephrology centers, while large country allocations concentrated around Spain, Germany, Austria, Bulgaria, Denmark, France, Greece, Italy, and Poland.\u003c/p>\n\u003c/div>\n\n\u003cdiv style=\"display:flex; flex-wrap:wrap; gap:14px;\">\n\u003cdiv style=\"flex:1 1 160px; background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:18px;\">\n\u003cdiv style=\"font-size:30px; line-height:36px; font-weight:650; color:#F2F2F2;\">54\u003c/div>\n\u003cdiv style=\"font-size:12px; line-height:1.4; font-weight:500; color:rgba(255,255,255,0.55); margin-top:6px;\">Phase II–III CKD / kidney failure trial records\u003c/div>\n\u003c/div>\n\u003cdiv style=\"flex:1 1 160px; background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:18px;\">\n\u003cdiv style=\"font-size:30px; line-height:36px; font-weight:650; color:#3FAE6F;\">33\u003c/div>\n\u003cdiv style=\"font-size:12px; line-height:1.4; font-weight:500; color:rgba(255,255,255,0.55); margin-top:6px;\">Phase III records\u003c/div>\n\u003c/div>\n\u003cdiv style=\"flex:1 1 160px; background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:18px;\">\n\u003cdiv style=\"font-size:30px; line-height:36px; font-weight:650; color:#3FAE6F;\">21\u003c/div>\n\u003cdiv style=\"font-size:12px; line-height:1.4; font-weight:500; color:rgba(255,255,255,0.55); margin-top:6px;\">Phase II records\u003c/div>\n\u003c/div>\n\u003c/div>\n\u003c/section>\n\n\u003cdiv style=\"height:1px; background:rgba(255,255,255,0.10); margin:0 0 64px 0;\">\u003c/div>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Top EU Site Anchors\">\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">Top EU site anchors were dialysis networks and recurring nephrology centers\u003c/h2>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">The top 10 site/legal-site anchors were ranked by recorded appearances in the available geography records. TritonLife Dializis Center Kft. led with \u003cstrong style=\"color:#F2F2F2;\">5 recorded site entries\u003c/strong>, followed by First Dialysis Services Bulgaria EAD with \u003cstrong style=\"color:#F2F2F2;\">3\u003c/strong>. Eight other recurring centers or legal-site names appeared \u003cstrong style=\"color:#F2F2F2;\">2 times each\u003c/strong>.\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"Top CKD / Kidney Failure Trial Site Anchors\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">Top site anchors by recorded entries\u003c/div>\n\n\u003cdiv style=\"display:flex; flex-direction:column; gap:14px;\">\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 40px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:13px; color:#F2F2F2;\">TritonLife Dializis Center Kft.\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:100%; height:12px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:13px;\">5\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 40px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:13px; color:#F2F2F2;\">First Dialysis Services Bulgaria EAD\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:60%; height:12px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:13px;\">3\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 40px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:13px; color:#F2F2F2;\">Nuvisan GmbH\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:40%; height:12px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:13px;\">2\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 40px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:13px; color:#F2F2F2;\">Amsterdam UMC / Amsterdam UMC Stichting\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:40%; height:12px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:13px;\">2\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 40px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:13px; color:#F2F2F2;\">Steno Diabetes Center Copenhagen\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:40%; height:12px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:13px;\">2\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 40px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:13px; color:#F2F2F2;\">Hospital Universitario Fundacion Jimenez Diaz\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:40%; height:12px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:13px;\">2\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 40px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:13px; color:#F2F2F2;\">Hospital Universitari Vall d’Hebron\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:40%; height:12px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:13px;\">2\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 40px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:13px; color:#F2F2F2;\">Hospital Clinico Universitario de Valencia\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:40%; height:12px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:13px;\">2\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 40px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:13px; color:#F2F2F2;\">Ziekenhuisgroep Twente Stichting\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:40%; height:12px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:13px;\">2\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 40px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:13px; color:#F2F2F2;\">Centre Hospitalier Universitaire de Nantes\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:40%; height:12px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:13px;\">2\u003c/div>\u003c/div>\n\u003c/div>\n\n\u003cdiv style=\"border-top:1px solid rgba(255,255,255,0.10); margin-top:20px; padding-top:10px; font-size:11px; color:rgba(255,255,255,0.45); letter-spacing:0.04em;\">CKD / kidney failure Phase II–III EU site appearances\u003c/div>\n\u003c/div>\n\n\u003cdiv class=\"conclusion-container\" data-conclusion-title=\"Top EU Site Anchors\" data-export-conclusion=\"true\" style=\"border-left:3px solid #3FAE6F; background:rgba(63,174,111,0.08); border-radius:8px; padding:18px 20px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:8px;\">Interpretation\u003c/div>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.78); margin:0;\">The site pattern is not dominated by one academic mega-center. Instead, CKD and kidney failure development relies on distributed nephrology, diabetes-kidney, and dialysis infrastructure, especially where trials target hemodialysis, renal anemia, hypertension, diabetes-related CKD, or kidney failure populations.\u003c/p>\n\u003c/div>\n\u003c/section>\n\n\u003cdiv style=\"height:1px; background:rgba(255,255,255,0.10); margin:0 0 64px 0;\">\u003c/div>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Phase Mix\">\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">Phase III represented most CKD / kidney failure activity\u003c/h2>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">Of the \u003cstrong style=\"color:#F2F2F2;\">54 included records\u003c/strong>, \u003cstrong style=\"color:#F2F2F2;\">33 were Phase III\u003c/strong> and \u003cstrong style=\"color:#F2F2F2;\">21 were Phase II\u003c/strong>. Phase III therefore represented \u003cstrong style=\"color:#F2F2F2;\">61.1%\u003c/strong> of the dataset, while Phase II represented \u003cstrong style=\"color:#F2F2F2;\">38.9%\u003c/strong>.\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"Phase Distribution\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">Phase distribution\u003c/div>\n\u003cdiv style=\"display:flex; flex-direction:column; gap:14px;\">\n\u003cdiv style=\"display:grid; grid-template-columns:90px 1fr 60px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">Phase III\u003c/div>\u003cdiv style=\"height:14px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:61.1%; height:14px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">61.1%\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:90px 1fr 60px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">Phase II\u003c/div>\u003cdiv style=\"height:14px; background:rgba(255,255,255,0.08); border-radius:999px;\">\u003cdiv style=\"width:38.9%; height:14px; background:#3FAE6F; border-radius:999px;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">38.9%\u003c/div>\u003c/div>\n\u003c/div>\n\u003cdiv style=\"border-top:1px solid rgba(255,255,255,0.10); margin-top:20px; padding-top:10px; font-size:11px; color:rgba(255,255,255,0.45); letter-spacing:0.04em;\">Phase II–III CKD / kidney failure records\u003c/div>\n\u003c/div>\n\n\u003cdiv class=\"conclusion-container\" data-conclusion-title=\"Phase Mix\" data-export-conclusion=\"true\" style=\"border-left:3px solid #3FAE6F; background:rgba(63,174,111,0.08); border-radius:8px; padding:18px 20px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:8px;\">Interpretation\u003c/div>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.78); margin:0;\">The Phase III tilt means site strategy is heavily shaped by execution scale, not just exploratory nephrology science. This explains why dialysis groups, multicenter national site lists, and countries with many smaller nephrology centers appear prominently.\u003c/p>\n\u003c/div>\n\u003c/section>\n\n\u003cdiv style=\"height:1px; background:rgba(255,255,255,0.10); margin:0 0 64px 0;\">\u003c/div>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Country Capacity Signals\">\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">Largest country allocation records point to Germany, Denmark, Austria, Spain, France and Greece\u003c/h2>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">The largest visible country-level participant allocations were Germany with \u003cstrong style=\"color:#F2F2F2;\">124\u003c/strong> and \u003cstrong style=\"color:#F2F2F2;\">64\u003c/strong> participants in renal anemia Phase III records, Denmark with \u003cstrong style=\"color:#F2F2F2;\">260\u003c/strong> participants in one Phase II CKD record, Austria with \u003cstrong style=\"color:#F2F2F2;\">220\u003c/strong>, Spain with \u003cstrong style=\"color:#F2F2F2;\">150\u003c/strong>, France with \u003cstrong style=\"color:#F2F2F2;\">100\u003c/strong>, and Greece with \u003cstrong style=\"color:#F2F2F2;\">100\u003c/strong>.\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"Selected High-Allocation Country Records\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">Selected high-allocation country records\u003c/div>\n\n\u003cdiv style=\"display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px;\">\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">Denmark\u003c/div>\u003cdiv style=\"font-size:28px; font-weight:650; color:#3FAE6F;\">260\u003c/div>\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">single Phase II CKD country allocation\u003c/div>\u003c/div>\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">Austria\u003c/div>\u003cdiv style=\"font-size:28px; font-weight:650; color:#3FAE6F;\">220\u003c/div>\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">single CKD / kidney failure allocation\u003c/div>\u003c/div>\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">Spain\u003c/div>\u003cdiv style=\"font-size:28px; font-weight:650; color:#3FAE6F;\">150\u003c/div>\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">large Phase III nephrology allocation\u003c/div>\u003c/div>\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">Germany\u003c/div>\u003cdiv style=\"font-size:28px; font-weight:650; color:#3FAE6F;\">124\u003c/div>\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">renal anemia Phase III allocation\u003c/div>\u003c/div>\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">France\u003c/div>\u003cdiv style=\"font-size:28px; font-weight:650; color:#3FAE6F;\">100\u003c/div>\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">Phase III stage 4–5 CKD / sarcopenia allocation\u003c/div>\u003c/div>\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">Greece\u003c/div>\u003cdiv style=\"font-size:28px; font-weight:650; color:#3FAE6F;\">100\u003c/div>\u003cdiv style=\"font-size:12px; color:rgba(255,255,255,0.55);\">large nephrology country allocation\u003c/div>\u003c/div>\n\u003c/div>\n\n\u003cdiv style=\"border-top:1px solid rgba(255,255,255,0.10); margin-top:20px; padding-top:10px; font-size:11px; color:rgba(255,255,255,0.45); letter-spacing:0.04em;\">Country-level participant allocations in CKD / kidney failure geography records\u003c/div>\n\u003c/div>\n\n\u003cdiv class=\"conclusion-container\" data-conclusion-title=\"Country Capacity Signals\" data-export-conclusion=\"true\" style=\"border-left:3px solid #3FAE6F; background:rgba(63,174,111,0.08); border-radius:8px; padding:18px 20px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:8px;\">Interpretation\u003c/div>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.78); margin:0;\">Country selection appears indication-dependent: dialysis and renal anemia studies can concentrate participants in fewer countries, while diabetes-related CKD and hypertension-linked CKD studies tend to use broader multi-country networks.\u003c/p>\n\u003c/div>\n\u003c/section>\n\n\u003cdiv style=\"height:1px; background:rgba(255,255,255,0.10); margin:0 0 64px 0;\">\u003c/div>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Disease Cluster Context\">\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">Disease clusters extend beyond generic CKD\u003c/h2>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">The CKD/kidney failure cohort contains several recurring clinical contexts: generic chronic kidney disease, end-stage renal/kidney disease, hemodialysis or dialysis-dependent kidney failure, renal anemia/anemia of CKD, CKD with hypertension, CKD with diabetes or obesity, kidney transplantation, and CKD with cardiovascular disease.\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"Clinical Context Map\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">Clinical context map\u003c/div>\n\n\u003cdiv style=\"display:flex; flex-wrap:wrap; gap:10px;\">\n\u003cspan style=\"padding:10px 12px; border-radius:999px; background:rgba(63,174,111,0.14); border:1px solid rgba(63,174,111,0.35); font-size:13px;\">Chronic kidney disease\u003c/span>\n\u003cspan style=\"padding:10px 12px; border-radius:999px; background:rgba(63,174,111,0.14); border:1px solid rgba(63,174,111,0.35); font-size:13px;\">End-stage renal disease\u003c/span>\n\u003cspan style=\"padding:10px 12px; border-radius:999px; background:rgba(63,174,111,0.14); border:1px solid rgba(63,174,111,0.35); font-size:13px;\">Hemodialysis\u003c/span>\n\u003cspan style=\"padding:10px 12px; border-radius:999px; background:rgba(63,174,111,0.14); border:1px solid rgba(63,174,111,0.35); font-size:13px;\">Renal anemia\u003c/span>\n\u003cspan style=\"pad","excerpt":"Across 54 CTIS Phase II–III CKD/kidney failure trial records, site activity clustered around dialysis/nephrology networks, with repeated appearances from TritonLife, First Dialysis Services Bulgaria, Nuvisan, Amsterdam UMC, Steno Diabetes Center Copenhagen, Vall d’Hebron, and Hospital Fundacion Jimenez Diaz.","coverImageUrl":null,"coverImageAlt":null,"author":null,"category":null,"tags":[],"metaTitle":"Which EU Sites Anchor Phase II–III CKD and Kidney Failure…","metaDescription":"Across 54 CTIS Phase II–III CKD/kidney failure trial records, site activity clustered around dialysis/nephrology networks, with repeated appearances from…","canonicalUrl":null,"robots":"index,follow","keywords":["nephrology","chronic kidney disease","CKD","kidney failure","end-stage renal disease","end-stage kidney disease","hemodialysis","dialysis","renal anemia","kidney transplantation","Phase II","Phase III","small molecule","peptide","protein","enzyme","cell therapy","Europe","EU clinical trial sites","CTIS"],"ogTitle":"Which EU Sites Anchor Phase II–III CKD and Kidney Failure…","ogDescription":"Across 54 CTIS Phase II–III CKD/kidney failure trial records, site activity clustered around dialysis/nephrology networks, with repeated appearances from…","ogImageUrl":"https://trialagents.com/og-default.png","ogImageAlt":"Which EU Sites Anchor Phase II–III CKD and Kidney Failure Trials?","ogType":"article","twitterCard":"summary_large_image","twitterTitle":"Which EU Sites Anchor Phase II–III CKD and Kidney Failure…","twitterDescription":"Across 54 CTIS Phase II–III CKD/kidney failure trial records, site activity clustered around dialysis/nephrology networks, with repeated appearances from…","twitterImageUrl":"https://trialagents.com/og-default.png","schemaJsonLd":{"@context":"https://schema.org","@graph":[{"@type":"Article","headline":"Which EU Sites Anchor Phase II–III CKD and Kidney Failure Trials?","description":"Across 54 CTIS Phase II–III CKD/kidney failure trial records, site activity clustered around dialysis/nephrology networks, with repeated appearances from TritonLife, First Dialysis Services Bulgaria, Nuvisan, Amsterdam UMC, Steno Diabetes Center Copenhagen, Vall d’Hebron, and Hospital Fundacion Jimenez Diaz.","datePublished":"2026-06-07","dateModified":"2026-06-07","author":{"@type":"Organization","name":"TrialAgents","url":"https://trialagents.com"},"publisher":{"@type":"Organization","name":"TrialAgents","url":"https://trialagents.com"},"mainEntityOfPage":"https://trialagents.com/reports/top-eu-ckd-kidney-failure-trial-sites"},{"@type":"Dataset","name":"Which EU Sites Anchor Phase II–III CKD and Kidney Failure Trials?","description":"Across 54 CTIS Phase II–III CKD/kidney failure trial records, site activity clustered around dialysis/nephrology networks, with repeated appearances from TritonLife, First Dialysis Services Bulgaria, Nuvisan, Amsterdam UMC, Steno Diabetes Center Copenhagen, Vall d’Hebron, and Hospital Fundacion Jimenez Diaz.","variableMeasured":["Top CKD / Kidney Failure Trial Site Anchors","Phase Distribution","Selected High-Allocation Country Records","Clinical Context Map"],"spatialCoverage":"Europe","isAccessibleForFree":true,"license":"https://creativecommons.org/licenses/by/4.0/","creator":{"@type":"Organization","name":"TrialAgents","url":"https://trialagents.com"}}]},"publishedAt":"2026-06-07T08:19:39.294Z","createdAt":"2026-06-07T08:19:40.001Z","updatedAt":"2026-06-07T08:19:40.001Z"}